NPS Reaches New 52-Week High (NPSP)

NEW YORK ( TheStreet) -- NPS Pharmaceuticals (Nasdaq: NPSP) hit a new 52-week high Monday as it is currently trading at $16.50, above its previous 52-week high of $16.47 with 389,952 shares traded as of 11:40 a.m. ET. Average volume has been 1.9 million shares over the past 30 days.

NPS has a market cap of $1.61 billion and is part of the health care sector and drugs industry. Shares are up 80.2% year to date as of the close of trading on Friday.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates NPS as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's revenue growth has not been good. You can view the full NPS Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..